Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
André J. Scheen. (2017) Pharmacotherapy of ‘treatment resistant’ type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 503-515.
Read now
Read now
Articles from other publishers (30)
Phil McEwan, Volker Foos, Becky Martin, Jieling Chen & Marc Evans. (2023)
Estimating the value of
sodium‐glucose cotransporter‐2
inhibitors within the context of contemporary guidelines and the totality of evidence
. Diabetes, Obesity and Metabolism 25:7, pages 1830-1838.
Crossref
Crossref
Kunika Saini, Smriti Sharma & Yousuf Khan. (2023) DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Sang Ho Oh, Su Jin Lee & Jongyoul Park. (2022) Effective data-driven precision medicine by cluster-applied deep reinforcement learning. Knowledge-Based Systems 256, pages 109877.
Crossref
Crossref
Sang Ho Oh, Jongyoul Park, Su Jin Lee, Seungyeon Kang & Jeonghoon Mo. (2022) Reinforcement learning-based expanded personalized diabetes treatment recommendation using South Korean electronic health records. Expert Systems with Applications 206, pages 117932.
Crossref
Crossref
Chunmei Xu, Liping He, Jing Zhang, Lusi Xu, Jianjun Dong & Lin Liao. (2022) The Cardiovascular Benefits and Infections Risk of SGLT2i versus Metformin in Type 2 Diabetes: A Systemic Review and Meta-Analysis. Metabolites 12:10, pages 979.
Crossref
Crossref
Alan J. Sinclair, Daniel Pennells & Ahmed H. Abdelhafiz. (2022) Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotype. Aging Clinical and Experimental Research 34:9, pages 1949-1967.
Crossref
Crossref
N. Van der Linden, S. Van Olst, S. Nekeman & C.A. Uyl‐de Groot. (2020) The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands. Diabetic Medicine 38:4.
Crossref
Crossref
Sang-Ho Oh, Su Jin Lee, Juhwan Noh & Jeonghoon Mo. (2021) Optimal treatment recommendations for diabetes patients using the Markov decision process along with the South Korean electronic health records. Scientific Reports 11:1.
Crossref
Crossref
Charalampos I. Liakos, Dimitrios P. Papadopoulos, Elias A. Sanidas, Maria I. Markou, Erifili E. Hatziagelaki, Charalampos A. Grassos, Maria L. Velliou & John D. Barbetseas. (2020) Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors). American Journal of Cardiovascular Drugs 21:2, pages 123-137.
Crossref
Crossref
Cyrus Desouza, Andreas R Kirk, Kamal K Mangla, Michael L Wolden & Ildiko Lingvay. (2020) Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs). BMJ Open Diabetes Research & Care 8:2, pages e001830.
Crossref
Crossref
Uday Hossain, Abhishek Kumar Das, Sumit Ghosh & Parames C. Sil. (2020) An overview on the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications. Food and Chemical Toxicology 145, pages 111738.
Crossref
Crossref
D. Wolmarans Wolmarans, S. Steyn Steyn & L. Brand Brand. (2020) Intensive initiation of insulin therapy in patients with newly diagnosed type 2 diabetes mellitus : a different take on current stepwise approaches. South African General Practitioner 1:3, pages 111-114.
Crossref
Crossref
Carlos K. H. Wong, Kenneth K. C. Man, Margaret Shi, Esther W. Chan, Chu Wa Ho, Emily T. Y. Tse, Ian C. K. Wong & Cindy L. K. Lam. (2019) Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study. PLOS Medicine 16:12, pages e1002999.
Crossref
Crossref
Joseph M. Pappachan, Cornelius J. Fernandez & Elias C. Chacko. (2019) Diabesity and antidiabetic drugs. Molecular Aspects of Medicine 66, pages 3-12.
Crossref
Crossref
Rebecca M Burne & Michal Abrahamowicz. (2017) Adjustment for time-dependent unmeasured confounders in marginal structural Cox models using validation sample data. Statistical Methods in Medical Research 28:2, pages 357-371.
Crossref
Crossref
Michael Willis, Christian Asseburg & Cheryl Neslusan. (2019) Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors. Diabetes Research and Clinical Practice 148, pages 222-233.
Crossref
Crossref
Néboa Zozaya, Margarita Capel, Susana Simón & Alfonso Soto-González. (2019) A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031987657.
Crossref
Crossref
Y. Jia, Y. Lao, H. Zhu, N. Li & S.‐W. Leung. (2018) Is metformin still the most efficacious first‐line oral hypoglycaemic drug in treating type 2 diabetes? A network meta‐analysis of randomized controlled trials. Obesity Reviews 20:1, pages 1-12.
Crossref
Crossref
Caroline M. Apovian, Jennifer Okemah & Patrick M. O’Neil. (2018) Body Weight Considerations in the Management of Type 2 Diabetes. Advances in Therapy 36:1, pages 44-58.
Crossref
Crossref
Hisamitsu Ishihara, Motonobu Anai, Hiroaki Seino, Toru Kitazawa, Hiroshi Ohashi, Masumi Ai, Masahiro Inoue, Midori Fujishiro, Takeshi Inazawa, Hisamoto Kuroda & Masayo Yamada. (2018) Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy. Diabetes Therapy 9:5, pages 2117-2125.
Crossref
Crossref
Francesco Zaccardi, Nafeesa N. Dhalwani, Jolyon Dales, Hamid Mani, Kamlesh Khunti, Melanie J. Davies & David R. Webb. (2018) Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 20:4, pages 985-997.
Crossref
Crossref
Lorraine Lipscombe, Gillian Booth, Sonia Butalia, Kaberi Dasgupta, Dean T. Eurich, Ronald Goldenberg, Nadia Khan, Lori MacCallum, Baiju R. Shah & Scot Simpson. (2018) Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Canadian Journal of Diabetes 42, pages S88-S103.
Crossref
Crossref
Min Kyong Moon. (2018) Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. The Journal of Korean Diabetes 19:1, pages 23.
Crossref
Crossref
Jian Li, Ying-hong Shao, Xiao-gang Wang, Yanping Gong, Chunlin Li & Yanhui Lu. (2018) Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis. Endocrine Journal 65:3, pages 335-344.
Crossref
Crossref
Min Kyong Moon, Kyu Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi & Nan-Hee Kim. (2017) Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. The Korean Journal of Internal Medicine 32:6, pages 974-983.
Crossref
Crossref
Michael Nauck & Birgit Wilhelm. (2017) Warum ist eine Kombination von Basalinsulin mit einem GLP-1-Rezeptoragonisten bei vielen Patienten mit Typ-2-Diabetes sinnvoll?Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?. MMW - Fortschritte der Medizin 159:S5, pages 7-15.
Crossref
Crossref
Stephen Kay, Amanda Strickson, Jorge Puelles, Ross Selby, Eugene Benson & Keith Tolley. (2017) Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Therapy 8:2, pages 251-273.
Crossref
Crossref
Min Kyong MoonKyu-Yeon HurSeung-Hyun KoSeok-O ParkByung-Wan LeeJin Hwa KimSang Youl RheeHyun Jin KimKyung Mook ChoiNan-Hee Kim. (2017) Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal 41:5, pages 357.
Crossref
Crossref
Joseph M. Pappachan & Ananth K. Viswanath. (2017) Medical Management of Diabesity: Do We Have Realistic Targets?. Current Diabetes Reports 17:1.
Crossref
Crossref
Andrew J. Krentz. (2016) Hypertension in type 2 diabetes: impact of glucose-lowering medications. Cardiovascular Endocrinology 5:4, pages 137-143.
Crossref
Crossref